View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
September 22, 2020updated 12 Jul 2022 11:35am

ARCA seeks approval to trial Covid-19 drug candidate AB201

ARCA biopharma has filed an investigational new drug (IND) application with the US Food and Drug Administration (FDA) to conduct a Phase IIb/III clinical trial of AB201 to treat hospitalised Covid-19 patients.

ARCA biopharma has filed an investigational new drug (IND) application with the US Food and Drug Administration (FDA) to conduct a Phase IIb/III clinical trial of AB201 to treat hospitalised Covid-19 patients.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The submission has been done under the Coronavirus Treatment Acceleration Programme (CTAP), a special emergency programme by the FDA for potential Covid-19 therapies.

Awaiting response from the FDA, ARCA expects to commence the Phase IIb portion of the sequential Phase IIb/III study of AB201 by the fourth quarter of the year.

ARCA biopharma president and CEO Michael Bristow said: “This IND submission is a key milestone in the clinical development of AB201.

“With what we believe to be a strong scientific rationale, safety data from prior human clinical trials in over 700 patients, and a well-defined regulatory pathway, we believe AB201 has potential as a therapeutic treatment for Covid-19, as well as other RNA virus-associated diseases.”

AB201, a small recombinant protein, is in the development stage to potentially treat RNA virus-associated diseases, with an initial focus on Covid-19.

It is a potent, selective inhibitor of tissue factor (TF), which is known to have a major role in the inflammatory response to viral infections and in the viral dissemination process.

AB210 also exhibits a mechanism that combines anti-coagulant, immuno-modulation, and anti-viral properties. This mechanism may help address pathologies caused by viral infections from different aspects.

The drug candidate was subjected to Phase I and II trials in more than 700 patients, including studies to prevent venous and arterial thrombosis. It was observed to inhibit the TF pathway and was well tolerated at therapeutic doses.

Recent research and former studies in non-human primates (NHPs) with Ebola or Marburg filoviruses showed that AB201 has potential for antiviral and anti-inflammatory activity, along with anticoagulant effects.

ARCA believes that these findings form a strong rationale for testing AB201 as a treatment for RNA virus-associated diseases, including Covid-19.

In February last year, ARCA announced plans to assess Gencaro as a genetically-targeted therapy in a pivotal Phase III trial for atrial fibrillation (AF) in patients with a certain type of heart failure (HF).

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena